spacer
home > epc > winter 2018 > marking safety
PUBLICATIONS
European Pharmaceutical Contractor

Marking Safety

“Sepsis is the most preventable cause of death” (1), and every hour it is not diagnosed will increase the probability of killing the patient by 7%; thus, recognising the early signs and symptoms is crucial. Severe sepsis is the leading cause of death in the noncoronary intensive care unit, with mortality rates between 30-50%.

According to Dr Adam Linder, “approximately one in five patients with sepsis who are admitted to hospital are at risk of developing severe sepsis within the first 24 hours” (2). Furthermore, it is also the biggest killer of children under five worldwide. Konrad Reinhart notes that 6 million babies from third-world countries and 10,000 of mothers die from the condition every year (1).

As sepsis often impacts the elderly (usually when they have some other condition), it is perhaps less talked about, but it also affects children. With such susceptible groups as these, anything that raises awareness among medical staff of the signs, symptoms, and dangers can only be a good thing.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Christene Leiper attended Sydney University, RMIT Melbourne, and Bond University in Australia and achieved a Professor of Medicine and Life Sciences at Bond University Queensland in 2006. She also undertook research at Edinburgh University, Scotland, as part of her PhD. Christene has been a Principal Investigator for clinical trials, which enables her to operate across many disciplinary boundaries within clinical research in a coherent and productive manner. In 2007, she was appointed Director of Research at a Scottish CRO, which in turn, led her to start her own CRO, Onorach, in 2009.
spacer
Professor Christene Leiper
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Aptus Clinical enters into a global partnership agreement with Artelo Biosciences

We are delighted to announce that Aptus Clinical has entered into an agreement with Artelo Biosciences to provide clinical development support the re-purposing of its high-potency dual cannabinoid agonist ART27.13 in oncology.
More info >>

White Papers

Digital Transformation of the Cold Chain

Sensitech EMEA

The Life Sciences cold chain is a seamless and interconnected global network of people, equipment, data and processes that helps to ensure the safety and integrity of our medicines and vaccines. Cold chain logistics spending totaled $13 billion in 2017, an investment designed to protect some $283 billion in Life Sciences cold chain products, growing at 19% annually.1 Sensitech Inc., a part of UTC Climate, Controls & Security, a unit of United Technology Corp., has played an essential part in the Life Sciences cold chain since 1990, providing a comprehensive set of solutions for manufacturers of biologics, prescription pharmaceuticals, clinical trial materials, and over-the-counter drugs. These solutions help to ensure product quality, patient safety, and regulatory compliance while helping to prevent theft and optimizing cold chain performance.
More info >>

 
Industry Events

SMi’s 9th Annual Biosimilars & Biobetters Conference

25-27 September 2018, Copthorne Tara Hotel, London, UK

Following the success of our previous events in both London and the US, Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement